| Name | Disufenton sodium |
| Description | Disufenton sodium (NXY-059), a new-type nitrone, exhibits potently neuroprotective effects. |
| In vitro | NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. [2] |
| In vivo | NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. [1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. [3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. [4] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 70 mg/mL (183.57 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 45 mg/mL (118.01 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.24 mM), Sonication is recommended.
|
| Keywords | ReactiveOxygenSpecies | Reactive Oxygen Species | OKN-007 | OKN 007 | Inhibitor | inhibit | Disufenton sodium | Disufenton |
| Inhibitors Related | Ethoxyquin | Kaolin | Allopurinol | Cysteamine hydrochloride | Ethyl linoleate | Magnesium acetate tetrahydrate | Inosine | L-Cystine | Copper Sulfate Pentahydrate | Dimethyl itaconate | L-Ascorbic acid sodium salt | Dimethyl phthalate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Pyroptosis Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Anti-Fibrosis Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
